stock · yahoo

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

600276.SS

$6.57
0.14 (2.17%)
polled · warming up

Below: live stock price for Jiangsu Hengrui Pharmaceuticals Co.,Ltd (600276.SS), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.

Day
+2.17%
+1.01
Week
-5.08%
-2.55
Month
-11.17%
-5.99
Year
-11.58%
-6.24
Prev close
$6.43
Volume
$9.56M
Market cap
$43.61B
Currency
USD (native CNY)

Financials

52w high
¥74.04
52w low
¥47.20
52w change
-12.40%
Day high
¥48.72
Day low
¥47.37
P/E (TTM)
39.05
Forward P/E
27.6
PEG
0.93
Price / Book
5.03
Beta (5Y)
0.17
Enterprise value
272.96B
EV / Revenue
8.38
EV / EBITDA
28.88
EPS (TTM)
¥1.22
Forward EPS
¥1.73
Dividend yield
0.43%
Dividend rate
¥0.20
Payout ratio
16.39%
Revenue (TTM)
32.56B
EBITDA
9.45B
Free cash flow
6.31B
Total cash
40.64B
Total debt
67.47M
Debt / Equity
0.11
Current ratio
9.23
Quick ratio
8.36
Profit margin
24.93%
Gross margin
86.27%
Return on assets
8.80%
Return on equity
14.54%
Shares outstanding
6.38B
Float
3.77B
Sector: HealthcareIndustry: Drug Manufacturers - Specialty & GenericHQ: ChinaEmployees: 20.6Kwww.hengrui.com

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.

Analyst & Risk

Consensus
No consensus available.
Analyst price target
Mean target · ? analysts
Beta (vs S&P 500)
0.17
very stable
52-week change
-12.40%
Debt / Equity
0.11
low leverage
Current ratio
9.23
Quick ratio
8.36
ROE
14.54%
ROA
8.80%
PEG ratio
0.93
potentially undervalued
EV / Revenue
8.38
EV / EBITDA
28.88
Revenue growth
13.00%
Earnings growth
13.30%
EBITDA
9.45B
Free cash flow
6.31B
Total cash
40.64B
Total debt
67.47M
Insider holdings
46.26%
Institutional
16.59%

Live discussion

Sign in to join the discussion.

  • No comments yet. Be the first.